Literature DB >> 19350365

Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy.

Antonio Barbato1, Roberto Iacone, Giovanni Tarantino, Ornella Russo, Paolo Sorrentino, Sonia Avallone, Ferruccio Galletti, Eduardo Farinaro, Elisabetta Della Valle, Pasquale Strazzullo.   

Abstract

To analyse the relationship of PAI-1 plasma levels to echographically determined liver steatosis and cardiometabolic risk factors in a randomly selected sample of 254 adult male participants of the Olivetti Heart Study. Accounting for age and ongoing pharmacological treatment, PAI-1 levels were directly (P < 0.005) associated with body mass index (BMI), waist circumference (WC), serum triglyceride (TG), total cholesterol, insulin, homeostasis model assessment index, gamma-glutamyl transpeptidase and peritoneal fat. At multiple linear regression (MLR) analysis, measures of adiposity and TG exerted significant and quantitatively similar effects on PAI-1 levels. A progressive rise in PAI-1 level was detected with increasing degree of steatosis. A stepwise MLR model was used to evaluate the relative power of cardiometabolic risk factors and liver steatosis on PAI-1 levels. Adjusting for alcohol intake, BMI, WC and peritoneal fat were alternatively included in the model with other variables found to be significantly associated with plasma PAI-1 level. Liver steatosis, serum TG and various indexes of adiposity each had a significant independent impact on PAI-1 plasma level and explained overall 23% of its variability. Abdominal fat, liver steatosis and serum TG levels were significant and independent determinants of PAI-1 plasma level in an unselected sample of adult male population upon adjustment for age and therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19350365     DOI: 10.1007/s11739-009-0240-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  46 in total

Review 1.  The adipocyte and hemostatic balance in obesity: studies of PAI-1.

Authors:  D J Loskutoff; F Samad
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-01       Impact factor: 8.311

2.  Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue.

Authors:  G Targher; L Bertolini; L Scala; G Zoppini; L Zenari; G Falezza
Journal:  Diabet Med       Date:  2005-10       Impact factor: 4.359

3.  Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.

Authors:  F Samad; D J Loskutoff
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

4.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors:  A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

5.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

6.  Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Health, Aging, and Body Composition study.

Authors:  Stefano Volpato; Marco Pahor; Luigi Ferrucci; Eleanor M Simonsick; Jack M Guralnik; Stephen B Kritchevsky; Renato Fellin; Tamara B Harris
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

7.  Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.

Authors:  Marie-Christine Alessi; Delphine Bastelica; Alenka Mavri; Pierre Morange; Bruno Berthet; Michel Grino; Irene Juhan-Vague
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-15       Impact factor: 8.311

8.  Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke.

Authors:  M Margaglione; G Di Minno; E Grandone; G Vecchione; E Celentano; G Cappucci; M Grilli; P Simone; S Panico; M Mancini
Journal:  Arterioscler Thromb       Date:  1994-11

9.  Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice.

Authors:  Robert S McCuskey; Yoshiya Ito; Graham R Robertson; Margaret K McCuskey; Michael Perry; Geoffrey C Farrell
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

10.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

Authors:  E Bonora; S Kiechl; J Willeit; F Oberhollenzer; G Egger; G Targher; M Alberiche; R C Bonadonna; M Muggeo
Journal:  Diabetes       Date:  1998-10       Impact factor: 9.461

View more
  10 in total

Review 1.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism.

Authors:  Matteo Nicola Dario Di Minno; Antonella Tufano; Anna Rusolillo; Giovanni Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome.

Authors:  Flavia Campos Corgosinho; Aline de Piano; Priscila L Sanches; Raquel M Campos; Patricia L Silva; June Carnier; Lila M Oyama; Lian Tock; Sergio Tufik; Marco T de Mello; Ana R Dâmaso
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 4.  Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance.

Authors:  Giovanni Tarantino; Silvia Savastano; Annamaria Colao
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

5.  Hepatic steatosis in overweight/obese females: new screening method for those at risk.

Authors:  Giovanni Tarantino; Genoveffa Pizza; Annamaria Colao; Fabrizio Pasanisi; Paolo Conca; Patrizia Colicchio; Carmine Finelli; Franco Contaldo; Carolina Di Somma; Silvia Savastano
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

Review 6.  Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

7.  SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease.

Authors:  Yuhan Liu; Fudong Yu; Yan Han; Qing Li; Zhujun Cao; Xiaogang Xiang; Shaowen Jiang; Xiaolin Wang; Jie Lu; Rongtao Lai; Hui Wang; Wei Cai; Shisan Bao; Qing Xie
Journal:  Sci Rep       Date:  2016-11-17       Impact factor: 4.379

8.  The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study.

Authors:  Stefanos Tyrovolas; Demosthenes B Panagiotakos; Ekavi N Georgousopoulou; Christina Chrysohoou; John Skoumas; William Pan; Dimitrios Tousoulis; Christos Pitsavos
Journal:  Therap Adv Gastroenterol       Date:  2019-06-23       Impact factor: 4.409

9.  Identification of Hub Genes Associated With Non-alcoholic Steatohepatitis Using Integrated Bioinformatics Analysis.

Authors:  Qingnan Meng; Xiaoying Li; Xuelian Xiong
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

10.  Young Hispanics at risk of type 2 diabetes display endothelial activation, subclinical inflammation and alterations of coagulation and fibrinolysis.

Authors:  Carlos O Mendivil; Ludivina Robles-Osorio; Edward S Horton; Osama Hamdy; Augusto Enrique Caballero
Journal:  Diabetol Metab Syndr       Date:  2013-07-19       Impact factor: 3.320

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.